At a Glance
- The Catalyst: The FDA issued a first-of-its-kind warning letter to Purolea Cosmetics Lab over the "Inappropriate Use of Artificial Intelligence".
- The Misconception: The FDA is not anti-AI; health authorities openly welcome technological advancement to support compliance.
- The Real Problem: The company failed to implement human governance, letting AI-generated compliance documents bypass rigorous human review and CGMP verification.
- The Golden Rule: AI can support your workflows, but authorized human representatives in the Quality Unit remain strictly accountable for compliance.
